Psychedelics

Awakn Life Sciences Corp. (NEO: AWKN) (Awakn), a biotechnology company with clinical operations developing and delivering medicines to better treat Addiction, is delighted to announce today that Professor Barbara Mason has joined as an advisor on Awakn's Clinical Advisory Board.

The board, which is chaired by Prof. David Nutt is focused on bringing new therapeutic paradigms to market as quickly as possible. Prof. Mason's experience in the translational medicine and treatment development of alcohol use disorder is world class.

Prof. Mason will join the Clinical Advisory Board which, Prof. David Nutt, Dr. Ben Sessa, Prof. Celia Morgan, Ann Mithoefer, Dr. Michael Mithoefer and Prof. Matt Johnson all currently sit on.

Professor Nutt commented; Professor Mason is another world-leading addition to an already stellar scientific advisory board. The experience and knowledge of our team is truly outstanding, and this will only strengthen us further. We thoroughly look forward to Barbara joining and having the impact we know she will.

Prof. Mason's Biography

Barbara J. Mason, Ph.D. is Director of the Pearson Center for Alcoholism and Addiction Research, Director of the Laboratory of Clinical Psychopharmacology, and Pearson Family Professor in the Department of Molecular Medicine at The Scripps Research Institute, La Jolla, CA. Dr. Mason's work in medication development for the treatment of substance use disorder has been recognized with the Smithers Distinguished Scientist Award from the American Society of Addiction Medicine, a MERIT Award from the National Institutes of Health (NIH), the Dean's Senior Clinical Research Award from the University of Miami School of Medicine, and the Andrew W. Mellon Foundation Teacher-Scientist Award from Weill Cornell University Medical College.

Prof. Mason conducted the seminal studies identifying nalmefene as having therapeutic potential for alcohol dependence; nalmefene (Selincro) has recently received regulatory approval for the treatment of alcohol dependence in the European Union and United Kingdom. Prof. Mason also served as overall Principal Investigator for the US 21-center trial of acamprosate (Campral) for the treatment of alcohol dependence which was conducted in support of FDA approval. Prof. Mason has served on the National Advisory Councils of the National Institute on Alcohol Abuse and Alcoholism (NIAAA) and the National Institute on Drug Abuse (NIDA). She has served as a guest expert for the U.S. Federal Food and Drug Administration (FDA) and as a reviewer of research grants for NIH and the Medical Research Council (MRC) of the UK.

Prof. Mason is an elected Fellow of the American College of Neuropsychopharmacology and has served as field editor for Neuropsychopharmacology, and as a member of multiple editorial boards, including Alcoholism: Clinical and Experimental Research, Journal of Substance Abuse, and Journal of Addiction Medicine.

Prof. Mason holds the Pearson Family Chair, an endowed professorship in alcohol and addiction research at The Scripps Research Institute and is currently directing a program of NIH-funded research that includes human laboratory studies and clinical trials to evaluate the therapeutic potential of novel medications for substance use disorders.

About Awakn Life Sciences Corp.

Awakn Life Sciences is a biotechnology company with clinical operations, researching, developing, and delivering medicine to better treat Addiction. Awakn's team consists of world leading chemists, scientists, psychiatrists, and psychologists who are developing and advancing the next generation of psychedelic drugs, therapies, and enabling technologies to treat Addiction. Awakn will also deliver evidence backed therapies for Addiction in clinics in the UK and Europe and through licencing partnerships globally.

www.awaknlifesciences.com | Twitter | LinkedIn | Facebook

Notice Regarding Forward-Looking Information

This news release contains certain forward-looking information and forward-looking statements, as defined in applicable securities laws (collectively referred to herein as "forward-looking statements"). Forward-looking statements reflect current expectations or beliefs regarding future events or the Company's future performance. All statements other than statements of historical fact are forward-looking statements. Often, but not always, forward-looking statements can be identified by the use of words such as "plans", "expects", "is expected", "budget", "scheduled", "estimates", "continues", "forecasts", "projects", "predicts", "intends", "anticipates", "targets" or "believes", or variations of, or the negatives of, such words and phrases or state that certain actions, events or results "may", "could", "would", "should", "might" or "will" be taken, occur or be achieved, including statements relating to the proposed NEO listing, and the business of the Company. All forward-looking statements, including those herein are qualified by this cautionary statement.

Although the Company believes that the expectations expressed in such statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those in the statements. There are certain factors that could cause actual results to differ materially from those in the forward-looking information. These include: whether conditions to the listing on NEO will be satisfied; the business plans and strategies of the Company, the ability of the Company to comply with all applicable governmental regulations in a highly regulated business; the inherent risks in investing in target companies or projects which have limited or no operating history and are engaged in activities currently considered illegal in some jurisdictions; changes in laws; limited operating history; reliance on management; requirements for additional financing; competition; inconsistent public opinion and perception regarding the medical-use of psychedelic drugs; and regulatory or political change. Readers are cautioned that the foregoing list of factors is not exhaustive of the factors that may affect forward-looking statements. Accordingly, readers should not place undue reliance on forward-looking statements. The forward-looking statements in this news release speak only as of the date of this news release or as of the date or dates specified in such statements.

Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking information. For more information on the Company, investors are encouraged to review the Company's public filings on SEDAR at www.sedar.com. The Company disclaims any intention or obligation to update or revise any forward- looking information, whether as a result of new information, future events or otherwise, other than as required by law.

This news release does not constitute an offer to sell, or a solicitation of an offer to buy, any securities in the United States. The Company's and Awakn's securities have not been and will not be registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act") or any state securities laws and may not be offered or sold within the United States or to U.S. Persons unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration is available.

Investor Enquiries:
KCSA Strategic Communications
Valter Pinto / Tim Regan
Phone: +1 (212) 896-1254
Awakn@KCSA.com

Media Enquiries:
America and Canada: KCSA Strategic Communications
Anne Donohoe
Adonohoe@KCSA.com

Rest of World: ROAD Communications
Paul Jarman / Anna Ramsey
Awakn@roadcommunications.co.uk

To view the source version of this press release, please visit https://www.newsfilecorp.com/release/90969

News Provided by Newsfile via QuoteMedia

awakn life sciences

Awakn Life Sciences Corp.


Keep reading...Show less
Lobe Sciences Enters into an Exclusive Agreement With iNGENu to Conduct Clinical Trials in Australia

Lobe Sciences Enters into an Exclusive Agreement With iNGENu to Conduct Clinical Trials in Australia

lobe sciences ltd. (CSE: LOBE) (OTCQB: LOBEF) ("Lobe" or the "Company"), a Canadian Biopharmaceutical company committed to discovering and developing psychedelic derived medicines for neurologic and brain disease today announced it has entered into an exclusive agreement with iNGENū Pty Ltd. ("iNGENū"), an Australian based Contract Research Organization (CRO), to design and conduct three or more clinical trials evaluating Lobe's proprietary psilocin analogues L-130 or L-131.

Philip Young, CEO of Lobe Sciences stated, "We are extremely happy to have partnered with iNGENū as we move our proprietary stable psilocin products into human clinical trials. iNGENū is an industry leading, full service CRO providing end-to-end services for companies developing cannabinoid and psychedelic drugs. We evaluated CRO's in multiple geographies and chose iNGENu as their core values match ours and our commitment to discovering transformational therapies for multiple Central Nervous System diseases and trauma."

News Provided by Newsfile via QuoteMedia

Keep reading...Show less
Optimi Health Unveils Canada's First Natural Therapeutic Psilocybin Product For Approved Patients

Optimi Health Unveils Canada's First Natural Therapeutic Psilocybin Product For Approved Patients

Blue Serenity brings science and compassion together, will cement Thomas Hartle's legacy as a Canadian psychedelic icon

Optimi and Hartle to host press conference today at 1:00 PM EST

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Nirvana Life Sciences

Nirvana Appoints New Chief Financial Officer

Nirvana Life Sciences Inc., (CSE:NIRV) ("Nirvana" or the "Company") a Canadian based life sciences company aimed at developing non-addictive chronic pain and addiction treatment products announces that Connie Hang has resigned as Chief Financial Officer of the Company. The Company thanks Ms. Hang for her work as CFO over the last 2 years, she will continue serving the Company as a Contractor.

Annie Storey, CPA, CA, BBA has been appointed as Chief Financial Officer, effective immediately. Ms. Storey, a director of the Company since 2017, brings over 25 years' experience in accounting, auditing, financial reporting and corporate services for Canadian and US public companies in the mining, entertainment and biotechnology sectors.

Keep reading...Show less
Optimi Health To Launch Therapeutic Psilocybin Product In Partnership With Patient Advocate Thomas Hartle

Optimi Health To Launch Therapeutic Psilocybin Product In Partnership With Patient Advocate Thomas Hartle

Optimi Health Corp. ( CSE: OPTI ) (OTCQX: OPTHF) (FRA: 8BN) ("Optimi" or the "Company"), a homegrown, Canadian company licensed by Health Canada to produce natural, scalable, and accessible psychedelic and functional mushrooms, as well as synthetic formulations for transformational human experiences, is pleased to announce that it has entered into a partnership with psilocybin patient advocate, Thomas Hartle. The parties have agreed to produce a Canadian-grown and harvested natural therapeutic psilocybin product for use by approved patients.

"Honouring Thomas's incredible optimism and appreciation for life with his own natural, Canadian-grown psilocybin product is something we will cherish as a company forever," said Bill Ciprick, CEO of Optimi Health. "We share Thomas's energy and passion for creating the perfect psilocybin experience, and we look forward to providing a vital service to Special Access Program patients while further demonstrating to regulators that psychedelic-assisted therapies can be integrated into our existing healthcare framework."

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less

COMPASS Pathways plc announces second quarter 2022 financial results and business highlights

-

Highlights:
  • Kabir Nath appointed as Chief Executive Officer
  • Phase III program submitted to FDA and under review
  • COMP360 phase II study in anorexia nervosa launched
  • Cash position at 30 June 2022 of $207.2 million
  • Conference call today at 8:00am ET (1:00pm UK)

COMPASS Pathways plc (Nasdaq: CMPS) ("COMPASS"), a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health, today reported its financial results for the second quarter 2022 and gave an update on recent progress across its business.

News Provided by GlobeNewswire via QuoteMedia

Keep reading...Show less
Morgan Stanley Positive in First Psychedelics Research Report

Morgan Stanley Positive in First Psychedelics Research Report

Morgan Stanley (NYSE:MS) has shared its first official commentary on the psychedelics industry.

The concept of investing in psychedelic medicine received a legitimate vote of confidence of sorts after the well-established banking firm released an introductory study evaluating the potential attached to the sector.

The research is intended to offer an initial look at the psychedelics investment proposal.

Keep reading...Show less

Latest Press Releases

Related News

×